Indeed, in tumour cells obtained from human glioma explants, we demonstrated that the majority (3 of 5) had previously-described mutations in p53, and most had the capacity for anchor-independent growth and expressed stem markers such as CD133, as reported for similar CSCs [45]. The gene discussed is TP53; the disease is glioma.